Biologics

Closed until further notice
#Antibody Fragments #argenx #Biologics #Phase III trial

Argenx discontinues Phase III Sjögren’s disease trial

argenx has revealed that it will discontinue the Phase III UNITY study of Vyvgart Hytrulo (efgartigimod subcutaneous – efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease.  The company said the decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop… Read More

#News

#Biologics #Cell Science #Drug discovery #Stability characterisation

Stop settling for the proxy – Why stability tests for biologics should measure intermolecular interactions directly

In this advertorial, Dr John Stenson from Malvern Panalytical explains why we need to move away from using ‘SLS mode’ on DLS instruments to determine B22 stability values for biologics. Reliable stability data: A growing need Stability testing for biologics is undergoing something of a revolution, with the introduction of… Read More

#Exclusive Content

Handshake jigsaw puzzle
#Biologics #Protein

Evonik partners with evitria on protein expression kit 

Evonik has announced a partnership with global antibody expression specialist evitria as it looks to accelerate its early biologics development.  The collaboration is set to advance a transient protein expression kit based on CHO cells for biopharmaceutical research and development. Evonik says the kit is designed to enable faster, more reliable,… Read More

#Business & Investment #News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Modernise and scale your antibody discovery programmes

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benchling
#News

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Meet the challenges of a shifting antibody discovery landscape

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Discover a modern data foundation for complex biologics

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In… Read More

Webinar date:
Supported by Benching
#News

Antibodies
#Antibodies #Biologics #Drug discovery #eBook

New eBook: B cell screening for antibody discovery

Thanks to their low toxicity and high specificity, therapeutic antibodies have enjoyed incredible market success across a range of disease categories. The global antibody discovery market, valued at $11.15 billion in 2025, is expected to surge to $35.35 billion by 2035. Experts predict this growth will… Read More

#News

eBook: B cell screening for antibody discovery
#Antibodies #Biologics #Drug discovery #eBook

B cell screening for antibody discovery

Download this exclusive eBook from Fluidic Sciences to learn more about: How the global antibody discovery market could evolve in the next 10 years How new technologies are improving efficiency and downstream success rates in antibody discovery Multiplexed rapid B cell screening and the future of antibody discovery… Read More

#eBooks #Resources

Antibody drug conjugates
#Antibody drug conjugate (ADC) #Biologics #Revvity

Preclinical screening platforms for Antibody-Drug Conjugate therapeutics

This advertorial is sponsored by Revvity. Antibody Drug Conjugates (ADCs) represent one of the most rapidly expanding oncology therapeutic categories. Hundreds of candidates are undergoing active clinical development, with about two hundred companies engaged in ADC development1. Recent regulatory adjustments within the pharmaceutical industry in the US have begun to… Read More

#Exclusive Content

Monoclonal antibody
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Discover AI infrastructure for modern antibody discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benching
#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benchling
#Webinars

Biologics
#Biologics #Guide

Download your guide to biologics stability parameters

A new Guide is now available to DDW readers from Nanotemper. Biologics characterisation requires more than one technique. Prometheus Panta combines multiple optical methods in a single platform for comprehensive protein characterisation; covering stability, purity, size, and aggregation. Download this practical Guide for definitions, tips, and relevance for biologics development. Read More

#News

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

Human brain
#Biologics #Denali Therapeutics #FDA #Hunter Syndrome

FDA approves Denali’s Hunter syndrome treatment

The US Food and Drug Administration (FDA) has granted accelerated approval for Avlayah (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier.   Avlayah is an enzyme replacement therapy indicated for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated… Read More

#News #Regulatory

#Bill & Melinda Gates Foundation #Biologics #Evotec #Funding #Infectious diseases #Monoclonal antibodies

Grant supports Evotec’s AI-driven optimisation of mAbs

Evotec subsidiary Just – Evotec Biologics has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilising its molecular design suite of computational technologies, called J.MD.  The investment continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of… Read More

#Business & Investment #News